Tyra Biosciences VP buys 2,925 shares in grant

Tyra Biosciences’ VP of Finance received 2,925 ESPP shares, correcting an earlier overstatement of her beneficial ownership.

Available on EDGAR 09/17/2026 - 07:27 PM EDT Accepted by SEC EDGAR 09/17/2026 - 07:26 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Tyra Biosciences, Inc. (TYRA) reported that Vice President, Finance (PAO) Yuliya Rueb acquired 2,925 shares of common stock on September 15, 2026 as a grant or award. The filing notes the shares were acquired under Tyra’s 2021 Employee Stock Purchase Plan, bringing her directly held common stock (including restricted stock units) to 11,258 shares. A prior Form 4 had overstated her beneficial ownership due to a clerical error, which this filing corrects.

Insider Trade Summary

Grant/Award: 2,925 shares

Grant/Award 1 txn

Insider Rueb Yuliya

Role Vice President, Finance (PAO)

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2, F3	2,925	$9.129	$27K

Holdings After Transaction: Common Stock — 11,258 shares (Direct)

Holdings Before and After: Common Stock, 8,333 to 11,258 shares (Direct)

Footnotes (3)

1. F1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
2. F2. Includes restricted stock units.
3. F3. The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4.

Key Figures

Shares acquired: 2,925 shares Reported price per share: $9.129 per share Shares held after transaction: 11,258 shares

3 metrics

Shares acquired 2,925 shares Common stock grant/award on September 15, 2026

Reported price per share $9.129 per share Acquisition of 2,925 common shares on September 15, 2026

Shares held after transaction 11,258 shares Direct beneficial ownership following the September 15, 2026 acquisition, including RSUs

Key Terms

Employee Stock Purchase Plan, restricted stock units, beneficially owned

3 terms

Employee Stock Purchase Plan financial

"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

restricted stock units financial

"Includes restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

beneficially owned financial

"overstated the number of securities beneficially owned by the Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TYRA disclose for Yuliya Rueb on September 15, 2026?

Tyra Biosciences disclosed that Vice President, Finance (PAO) Yuliya Rueb acquired 2,925 shares of common stock on September 15, 2026 as a grant or award, at a reported price of $9.129 per share, under the company’s 2021 Employee Stock Purchase Plan.

How many TYRA shares does Yuliya Rueb hold after this Form 4 transaction?

After the reported acquisition, Yuliya Rueb directly holds 11,258 shares of Tyra Biosciences common stock. This total includes restricted stock units, as specifically noted in the filing’s footnotes.

What plan was used for the 2,925-share acquisition reported for TYRA?

The 2,925 shares of Tyra Biosciences common stock acquired by Yuliya Rueb were obtained under the company’s 2021 Employee Stock Purchase Plan, according to the transaction footnote linked to this Form 4 entry.

Did the TYRA Form 4 mention any correction to prior insider ownership figures?

Yes. The Form 4 states that a previously filed Form 4 overstated the number of securities beneficially owned by Yuliya Rueb in column 5 due to a clerical error, and that this current Form 4 corrects that ownership figure.

Was the TYRA insider trade made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not affirmatively checked, and there is no footnote stating the transaction was made pursuant to a Rule 10b5-1 trading plan, so no such plan is reported in connection with this acquisition.

Is Yuliya Rueb’s TYRA ownership reported as direct or indirect in this Form 4?

The Form 4 reports Yuliya Rueb’s post-transaction holding of 11,258 shares as direct ownership of Tyra Biosciences common stock, with no separate entity or indirect ownership structure indicated for this position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rueb Yuliya

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Finance (PAO)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		A(1)	V	2,925	A	$9.129	11,258(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

2. Includes restricted stock units.

3. The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4.

	/s/ Ali D. Fawaz, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)